Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Capital Expenditures (2017 - 2021)

Rein Therapeutics (RNTX) has disclosed Capital Expenditures for 4 consecutive years, with $5000.0 as the latest value for Q3 2021.

  • On a quarterly basis, Capital Expenditures changed N/A to $5000.0 in Q3 2021 year-over-year; TTM through Dec 2021 was $157000.0, a 685.0% increase, with the full-year FY2021 number at $157000.0, up 3040.0% from a year prior.
  • Capital Expenditures was $5000.0 for Q3 2021 at Rein Therapeutics, down from $67000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.3 million in Q3 2018 to a low of $4000.0 in Q2 2019.
  • A 4-year average of $221266.7 and a median of $38000.0 in 2017 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: soared 8337.04% in 2018, then crashed 99.78% in 2019.
  • Rein Therapeutics' Capital Expenditures stood at $68000.0 in 2017, then surged by 455.88% to $378000.0 in 2018, then plummeted by 96.03% to $15000.0 in 2019, then plummeted by 66.67% to $5000.0 in 2021.
  • Per Business Quant, the three most recent readings for RNTX's Capital Expenditures are $5000.0 (Q3 2021), $67000.0 (Q2 2021), and $85000.0 (Q1 2021).